

FACULTY

A.H Awada, Brussels (Belgium)	W.J. Gradishar, Chicago - IL (USA)
C. Boni, Reggio Emilia (Italy)	R. Gralla, New York - NY (USA)
E. Bria, Verona (Italy)	V. Guarneri, Padua (Italy)
M. Campone, Nantes Saint-Herblain (France)	A. Howell, Manchester (UK)
S. Cinieri, Brindisi (Italy)	C.A. Hudis, New York - NY (USA)
P. Conte, Padua (Italy)	C.L. Loprinzi, Rochester - MN (USA)
M. Cristofanilli, Philadelphia - PA (USA)	R. Maurizi Enrici, Rome (Italy)
R. Danesi, Pisa (Italy)	F. Montemurro, Turin (Italy)
E. De Azambuja, Brussels (Belgium)	M. Mottolese, Rome (Italy)
J.S. De Bono, Sutton (UK)	G. Naso, Rome (Italy)
M. De Laurentiis, Naples (Italy)	F. Nolè, Milan (Italy)
S. De Placido, Naples (Italy)	R. Orecchia, Milan (Italy)
L. Del Mastro, Genoa (Italy)	E. Perez, Jacksonville - FL (USA)
C. Desmedt, Brussels (Belgium)	P. Pinnarò, Rome (Italy)
F. Di Costanzo, Florence (Italy)	M. Pollak, Montreal - QC (Canada)
A. Di Leo, Prato (Italy)	K.I. Pritchard, Toronto (Canada)
V. Dieras, Paris (France)	P. Pronzato, Genoa (Italy)
A.D. Elias, Aurora - CO (USA)	F. Puglisi, Udine (Italy)
A. Fabi, Rome (Italy)	D. Santini (Rome, Italy)
A. Farooki, New York - NY (USA)	S.M. Tolaney, Boston - MA (USA)
T. Gamucci (Sora, Italy)	G. Tortora, Verona (Italy)
K. Gelmon, Vancouver - BC (Canada)	G. Von Minckwitz, Neu-Isenburg (Germany)
M. Gnant, Wien (Austria)	

PRINCIPAL SPONSORS

ELI LILLY ROCHE

MAJOR SPONSORS



SPONSOR



We also thank Italfarmaco and Pierre Fabre for their support to the Congress

PROVIDER E.C.M.

AIM Education

Via G. Ripamonti, 129 - 20141 Milan
Ph. +39 02 56601.1 - Fax +39 02 70048585
cme@aimgroup.eu - www.aimeducation.it

ORGANIZING SECRETARIAT



AIM Group International

Rome office: Via Flaminia, 1068 - 00189 Rome
Ph. 06 33053.1 - Fax 06 33053249
breastcancer2013@aimgroup.eu
<http://web.aimgroupinternational.com/2013/breastcancer>



3rd International Meeting on New Drugs in Breast Cancer

ROME, NOVEMBER 14 - 15, 2013

Regina Elena National Cancer Institute
Bastianelli Congress Center

PRESIDENT: *Francesco Cognetti*

WELCOME LETTER

Dear Colleagues and Friends,

It is with great pleasure that, following the great success reached during the previous two editions, I am pleased to announce that the 3rd International Meeting on New Drugs in Breast Cancer will be held in Rome at the Regina Elena National Cancer Institute, on November 14-15, 2013.

Breast cancer represents a continuing challenge to physicians and patients. A better understanding of breast cancer biology has produced great improvement in the treatment (cure, prolongation of survival, palliation of symptoms) based on the availability of novel targeted therapeutics. The speed of these progresses has been very fast also during the past two years.

The Scientific Programme of the Meeting will include topics on Target Therapy, on Chemotherapy and on Hormonal therapy, but also some lectures and video conferences on more general aspects as well as biology of hormonal pathways, adjuvant treatments, prognostic factors or specific items (circulating tumor cells, cancer stem cells, management of small tumors, etc).

The programme was designed in the pursuit of excellence and all lectures will be presented by an international distinguished outstanding faculty which will report all their experiences and developments.

The meeting will take place again in the beautiful city of Rome and I am sure there will be plenty of opportunities for a unique and enjoyable stay in our city.

Francesco Cognetti



THURSDAY, NOVEMBER 14

1ST SESSION: TARGET THERAPY

Presenting: F. Cognetti

9.00 LECTURE: “Prediction of benefit from systemic adjuvant therapies for breast cancer”
(E. Perez)

HER2 family inhibitors

Chairmen: M. De Laurentiis, F. Montemurro

9.30 Adjuvant and neoadjuvant therapy in HER2 positive patients (P. Conte)

10.00 New Her2-directed combinations in metastatic setting (K. Gelmon)

10.20 The future options of T-DM1 (V. Dieras)

10.40 Afatinib: the new irreversible Erb-B family blocker (E. De Azambuja)

11.00 Novel markers of resistance in HER2 inhibitors (G. Tortora)

11.20 Discussion

11.40 – 11.50 Coffee break

Angiogenesis family inhibitors

Chairmen: E. Bria, S. Cinieri

11.50 Bevacizumab and neoadjuvant therapy (G. Von Minckwitz)

12.10 Anti VEGF and HER2 inhibitors combination (K.I. Pritchard)

12.30 Ramucirumab: new developments (V. Guarneri)

Anti-IGFRs

12.50 Targeting insulin and IGF signaling in breast cancer: metformin, kinase inhibitors, and antibodies (M. Pollak)

13.10 – 14.10 Buffet Lunch

PI3K inhibitors

14.10 BKM120: efficacy in triple negative and in endocrine sensitive MBC tumors (F. Nolè)

14.30 Discussion

Mammalian target of rapamycin pathway inhibitors

Chairmen: F. Puglisi, T. Gamucci

14.50 Everolimus in HER2 positive tumors: where are we? (M. Gnant)

15.10 Management of Metabolic Effects associated with Anticancer Agents targeting the PI3K-Akt-mTOR Pathway (A. Farooki)

Met inhibitors

15.30 Tivantinib and cabozantinib: treatment selection in advanced disease (S.M. Tolaney)

15.50 Discussion

Presenting: R. Maurizi Enrici, P. Pinnarò

16.10 LECTURE: “New radiotherapeutic techniques in early breast cancer” (R. Orecchia)

16.40 Discussion

Presenting: F. Di Costanzo

17.00 LECTURE: “Treatment for advanced breast cancer: lights and shadows ” (E. Perez)

FRIDAY, NOVEMBER 15

Presenting: G. Naso

9.00 LECTURE: “Cancer micrometastases and circulating tumor cells” (M. Cristofanilli)

9.30 LECTURE: “Management of small tumors” (A.D. Elias)

2ND SESSION - CYTOTOXIC DRUGS

Chairmen: S. De Placido, A. Fabi

10.00 Nanoparticle albumin-bound: where are we? (W.J. Gradishar)

10.20 Delivered liposomal drug: too good to be old (R. Danesi)

10.40 NKTR-102 and Ganetespib: new perspectives (A.H. Awada)

11.00 – 11.10 Coffee break

The next step of antiemetic treatment

11.10 NETUPITANT: the new association of antiemetic drugs (R. Gralla)

11.30 The revolution in the prevention and treatment of bone metastases (D. Santini)

Videoconference

Presenting: A. Di Leo

11.50 *New generation sequencing for gene expression profiling* (C. Desmedt)

12.20 Discussion

3RD SESSION - HORMONAL THERAPY

Presenting: P. Pronzato

12.40 LECTURE: “Endocrine therapy in early breast cancer” (K. Gelmon)

13.10 LECTURE: “Mechanisms of resistance to endocrine therapy” (K.I. Pritchard)

13.40 – 14.40 Buffet Lunch

Chairmen: L. Del Mastro, C. Boni

14.40 Hormonal therapy and mTOR inhibitors: future directions (M. Campone)

15.00 Polyendocrine therapy in postmenopausal women: lights and shadows (P. Pronzato)

15.20 Anti-hormonal Strategies: Bicalutamide and Abiraterone (J.S. De Bono)

15.40 Non-estrogenic management of hot flashes (C.L. Loprinzi)

16.00 Discussion

Videoconference

Presenting: F. Cognetti

16.20 *Prognostic factors: state of art in early breast cancer* (C.A. Hudis)

New horizons

Presenting: M. Mottolese

16.50 LECTURE: “Targeting tumor stroma and cancer stem cells: new potential target therapies” (A. Howell)

17.20 Discussion

17.40 **Conclusions** F. Cognetti

SCIENTIFIC COMMITTEE

E. Bria (Verona, I)

P. Conte (Padua, I)

M. De Laurentiis (Naples, I)

S. De Placido (Naples, I)

L. Del Mastro (Genoa, I)

A. Di Leo (Prato, I)

L. Gianni (Milan, I)

P. Pronzato (Genoa, I)

G. Tortora (Verona, I)

LOCAL SCIENTIFIC COORDINATOR

Alessandra Fabi

LOCAL SCIENTIFIC SECRETARIAT

Paolo Carlini

Cecilia Nisticò

Paola Papaldo

Regina Elena National Cancer Institute

Via Elio Chianesi, 53 - 00144 Rome, Italy

CONGRESS VENUE AND GENERAL INFORMATION

The Scientific Sessions will be held on November 14-15, 2013 at the Regina Elena National Cancer Institute - “Raffaele Bastianelli” Congress Centre (via Fermo Ognibene, 23 - 00144 Rome).

Language

The official language of the Congress is English. Simultaneous translation will not be provided.

Certificate of attendance

Certificates will be issued to all registered participants who will expressly make request at the Secretariat Desk at the end of the Congress.

ECM - Educazione Continua in Medicina – for Italian delegates only

L'evento (corso/congresso) è inserito nel Piano Formativo anno 2013 AIM Education – Provider nr. 93 (www.aimeducation.it) ed è stato accreditato presso la Commissione Nazionale per la Formazione Continua esclusivamente per la Figura Professionale **Medico Chirurgo** con specializzazione nelle seguenti discipline oncologia, radioterapia, chirurgia generale, radiodiagnostica; per la Figura Professionale di **Farmacista** con specializzazione nella seguente disciplina farmacia ospedaliera; per la Figura Professionale di **Biologo** con specializzazione nella seguente disciplina Biologo; per la Figura Professionale di **Infermiere** con specializzazione nella seguente disciplina Infermiere, per un numero massimo di 200 partecipanti. Oltre tale numero e per professioni/discipline differenti da quelle accreditate non sarà possibile rilasciare i crediti formativi. Si precisa che i crediti verranno erogati a fronte di una partecipazione del 100% ai lavori scientifici e del superamento della prova di apprendimento con almeno il 75% delle risposte corrette.

REGISTRATION INFORMATION

· Registration Fee	€ 182,00 (VAT 21% included)
· Registration for doctors/nurses of Regina Elena National Cancer Institute	FREE (until September 1st, 2013)
· Postgraduate students	FREE (until September 1st, 2013)

The registration fee entitles delegates to the following:

- entry to scientific sessions
- 1 coffee break and 1 buffet lunch on November 14 and 15, 2013
- CME credits
- congress material
- certificate of attendance

For further information or to register please visit the official website:

<http://web.aimgroupinternational.com/2013/breastcancer>

or write to: breastcancer2013@aimgroup.eu